Psoriasis research studies

A new approach to anti-psoriasis drug assessment

Preclinical anti-psoriasis efficacy studies

Innovative anti-psoriasis drug assays for better drug development

Genoskin uses an entirely new approach to help biotech and pharmaceutical companies assess the efficacy of anti-psoriasis compounds and drugs. We combine real human data generation platforms, hi-tech expertise and artificial intelligence to deliver reliable, unbiased, first-in-human data on your anti-psoriasis treatment without actually involving humans. Below you’ll find an overview of why and how we do it.


Genoskin’s human data generation platforms are standardized for reproducible results.

T-cell driven

Our anti-psoriasis studies are based on the live response of our unique T-cell driven human psoriasis skin model.


We study efficacy for both biologics and small-molecule drugs and for different administration routes.


We use cutting-edge AI-based technology to generate in-depth data for prophylactic and therapeutic drugs.

Psoriasis, a condition with no cure

Finding new ways to help science move forward

Psoriasis is an immune-mediated skin disease that affects some 125 million people worldwide according to the World Psoriasis Day consortium. The condition has a big impact on patients who are also at risk of experiencing a range of associated diseases, such as metabolic syndrome, stroke, heart attack, cardiovascular disease and depression. About 40% of patients with psoriasis develop psoriatic arthritis. To date, anti-psoriasis drugs don’t provide a cure, even though biologics have helped improve symptoms. Here at Genoskin, we aim to provide drug developers with innovative solutions to help them find a cure.

Anti-psoriasis efficacy studies for all types of treatments

High-quality data for prophylactic & therapeutic treatments

To help biotech and pharmaceutical companies assess the efficacy of anti-psoriasis drugs & compounds, Genoskin uses its unique InflammaSkin® ex vivo psoriasis skin model. To this day, this live and immunocompetent human skin model is the only ex vivo skin model to feature T-cell mediated inflammation. Our high-level preclinical drug studies can be conducted for anti-psoriasis treatments that are designed for prophylactic or therapeutic use. For prophylactic treatments, the InflammaSkin® ex vivo human skin model will be treated at day 0 to show efficacy against the onset of the condition. Therapeutic compounds and treatments will only be administered at day 3 to research efficacy.

Prophylactic and therapeutic antipsoriasis studies

Anti-psoriasis efficacy studies for biologic & conventional drugs

Research the efficacy of all available options

InflammaSkin® psoriasis skin model can be used to assess the efficacy of anti-inflammatory drugs targeting T-cells as well as more specific psoriasis targets such as IL-17, IL-22 and TNF-α. It is also possible to study other targets to fit your needs and requirements. Our InflammaSkin® model is compatible with conventional, small-molecule drugs and has also been validated for biologics to study drug efficacy. Below you’ll see the results of an anti-TNF alfa efficacy study after subcutaneous injection of the Adalimumab biologic.

Cytokine analysis biologic IL-17A adalimumab-100
Cytokine analysis biologic IL-22 Adalimumab-100
Psoriasis research biologic INF-g Adalimumab-100

Adalimumab was injected at D3 under 2 conditions : 5nM and 50nM with 3 replicates for each condition. Measurement of psoriasis-relevant cytokines released shows a dose-response down-regulation for IL-17A, IL-22, INF-γ. These results prove the adequacy of the InflammaSkin® platform to assess the efficacy of subcutaneously injectable anti-psoriasis drugs. For more detailed results, don’t hesitate to download the scientific poster.

Anti-psoriasis efficacy studies for multiple administration routes

And discover the best way to deliver your anti-psoriasis treatment

To date, Genoskin is the only company in the world that provides a live ex vivo human skin model that allows testing subcutaneous injection. For the purpose of anti-psoriasis studies, we can therefore conduct efficacy studies after topical or subcutaneous administration. Moreover, our InflammaSkin® platform can also help you define the most efficient administration route for drug delivery.


Subcutaneous injection

Topical application

Below you’ll find the study results on the pharmacological efficacy of two prophylactic anti-inflammatory drugs: Betamethasone Dipropionate (BDP gel) and a PDE4 inhibitor cream, which were applied topically on a daily basis, from D0 to D6.

Anti-psoriasis study after topical administration IL-17A BDP-PDE4-100
Anti-psoriasis study after topical administration IL-22 BDP-PDE4-100
Psoriasis study topical administration INF-g BDP-PDE4-100

After the experiment, the level of Th17/Th1-related inflammatory cytokines was assessed in the culture medium using our MSD technology for pro-inflammatory markers IL-17A & INF-ᵞ and ELISA for IL-22. The study involved 3 donors. *P<.05, **P<.01, ***P<0.001. The results expressed as the percentage difference compared to untreated control are mean values ± SEM from independent experiments (n=3). A one-way ANOVA statistical test was used to compare treatment effect by BDP and PDE4 inhibitor versus matching vehicle control. For more detailed results don’t hesitate to download the scientific poster.

Study efficacy for multiple donors

Multiple donors to increase study & research relevance

Since our human data generation platforms only contain donated skin, it is possible to conduct studies on multiple donors to obtain relevant and reliable results. The variations in our skin models are donor-dependent and are one of the great strengths of our approach, as they reflect natural biological variations in the general population, allowing for more accurate and relevant study results.

Variety of donors for psoriasis studies

High-quality studies and research on every level

Cutting-edge technology for reliable in-depth analysis

The results obtained from our InflammaSkin® data generation platform are analysed by a team of experts in human skin and its immunology, who work with cutting-edge tools to help you obtain the results that help your research move forward. Our experts master the traditional, standard tests as well as the latest technology to assess skin inflammation, epidermal activation and tissue integrity. We focus on generating unbiased and accurate human data to support safer and faster drug development. Below you’ll find an illustration of our psoriasis research study process.

Interested in our psoriasis research studies?

Don’t hesitate to contact us so we can help your research move forward. Please note that the InflammaSkin® model we use requires special care to function to its full potential . The model is therefore only available as an in-house service so our skin experts can help you study the efficacy of anti-psoriasis drugs & compounds under the best conditions.

Scientific publications using our technology & services

See how others use our Inflammaskin® model and services

February 2021 - Calcipotriol/Betamethasone Dipropionate Foam Inhibits Th17 Cytokine Secretion and Improves Epidermal Barrier Markers in a Human Th17 Skin Inflammation Model

October 2020 - Development and characterization of a human Th17 driven ex vivo skin inflammation model

January 2020 - Translational drug discovery and development with the use of tissue-relevant biomarkers: Towards more physiological relevance and better prediction of clinical efficacy

October 2019 - Improvements of both inflammation and skin barrier in a human Th17 skin inflammation model by topical treatment with fixed-dose combination calcipotriene/betamethasone dipropionate foam

September 2019 - Poster - Evaluation of pharmacological responses to subcutaneous injection of adalimumab in InflammaSkin®, a full-thickness human ex vivo skin model reproducing key features of psoriatic lesions

May 2018 - Poster - 3D imaging of cleared ex vivo normal human skin, skin appendages and psoriasiform skin lesion using light-sheet microscopy

September 2017 - Poster - Evaluation of pharmacological responses in a fully human ex vivo skin model following in situ T cell activation with Th17/Th1 psoriasis-like phenotype

A specific study has sparked your interest?

Don’t hesitate to contact us so we can explain our approach or give you advice to help your research move forward. Please note that the InflammaSkin® model is only available as an in-house service but don’t hesitate to use our 10 years of experience to conduct the studies you need.